Dipeptidyl peptidase-4 and kidney fibrosis in diabetes

Fibrogenesis and Tissue Repair

Volumn 9, Issue 1, 2016, Pages

  Shi, Sen ^a,b   Koya, Daisuke ^a   Kanasaki, Keizo ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; Dipeptidyl peptidase 4; Kidney protection

Indexed keywords

ALOGLIPTIN; BETA1 INTEGRIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; INSULIN; LC 15 0444; LINAGLIPTIN; MICRORNA; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; END STAGE RENAL DISEASE; ENZYME ACTIVITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FIBROSIS; KIDNEY ISCHEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN PROTEIN INTERACTION; RENAL PROTECTION; REVIEW; SIDE EFFECT; WEIGHT GAIN;

EID: 84957629803     PISSN: None     EISSN: 17551536     Source Type: Journal    
DOI: 10.1186/s13069-016-0038-0     Document Type: Review

References (110)

1. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes care. 2011;34(6):1249-57. doi:10.2337/dc11-0442.
2. Shi Y, Hu FB. The global implications of diabetes and cancer. Lancet. 2014; 383(9933):1947-8. doi:10.1016/S0140-6736(14)60886-2.
3. Parving HH. Diabetic nephropathy: prevention and treatment. Kidney international. 2001;60(5):2041-55. doi:10.1046/j.1523-1755.2001.00020.x.
4. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. The New England journal of medicine. 2002; 346(15):1145-51. doi:10.1056/NEJMcp01 1 773.
5. Mazze RS, Bergenstal R, Ginsberg B. Intensified diabetes management: lessons from the diabetes control and complications trial. Int J Clin Pharmacol Ther. 199533(1)43-51.
6. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj. 2000;321(7258):405-12.
7. Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia. 2008;51(5): 714-25. doi:10.1007/s00125-008-0961-8.
8. Alter ML, Ott IM, von Websky K, Tsuprykov O, Sharkovska Y, Krause-Relle K, et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney & blood pressure research. 2012;36(1):119-30. doi:10.1159/000341487.
9. Yamagishi S, Fukami K, Matsui T. Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovasc Diabetol. 2015;14:2. doi:10.1186/s12933-015-0176-5.
10. Haluzik M, Frolik J, Rychlik I. Renal effects of DPP-4 inhibitors: a focus on microalbuminuria. Int J Endocrinol. 2013;2013:895102. doi:10.1155/2013/895102.
11. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40(3):209-94. doi:10.1080/713609354.
12. 12 Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science. 1993;261(5120):466-9.
13. Lopez-Otin C, Matrisian LM. Emerging roles ofproteases in tumour suppression. Nat Rev Cancer. 2007;7(10):800-8. doi:10.1038/nrc2228.
14. Lu G, Hu Y, Wang Q, Qi J, Gao F, Li Y, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature. 2013;500(7461):227-31. doi:10.1038/nature12328.
15. Kahne T, Lendeckel U, Wrenger S, Neubert K, Ansorge S, Reinhold D. Dipeptidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth (review). Int J Mol Med. 1999;4(1):3-15.
16. Deacon CF. What do we know about the secretion and degradation of incretin hormones? Regul Pept. 2005;128(2):117-24. doi:10.1016/j. regpep.2004.06.007.
17. Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev. 2014;35(6):992-1019. doi:10.1210/er.2014-1035.
18. Boerrigter G, Costello-Boerrigter LC, Harty GJ, Lapp H, Burnett Jr JC. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol. 2007;292(2):R897-901. doi:10.1152/ajpregu.00569.2006.
19. Brandt I, Lambeir AM, Ketelslegers JM, Vanderheyden M, Scharpe S, De Meester I. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem. 2006;52(1):82-7. doi:10.1373/clinchem.2005.057638.
20. Mentlein R. Dipeptidyl-peptidase IV, (CD26)-role in the inactivation of regulatory peptides. Regul Pept. 1999;85(1):9-24.
21. Marchetti C, Di Carlo A, Facchiano F, Senatore C, De Cristofaro R, Luzi A, et al. High mobility group box 1 is a novel substrate ofdipeptidyl peptidase-IV. Diabetologia. 2012;55(1):236-44. doi:10.1007/s00125-011-2213-6.
22. Kirby M, Yu DM, O'Connor S, Gorrell MD. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clinical science. 2010;118(1): 31-41. doi:10.1042/CS20090047.
23. Gorrell MD, Gysbers V, McCaughan GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol. 2001;54(3):249-64.
24. De Meester I, Korom S, Van Damme J, Scharpe S. CD26, let it cut or cut it down. Immunology today. 1999;20(8):367-75.
25. Chien CH, Huang LH, Chou CY, Chen YS, Han YS, Chang GG, et al. One site mutation disrupts dimer formation in human DPP-IV proteins. J Biol Chem. 2004;279(50):52338-45. doi:10.1074/jbc. M406185200.
26. Durinx C, Lambeir AM, Bosmans E, Falmagne JB, Berghmans R, Haemers A, et al. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem. 2000;267(17):5608-13.
27. Cordero OJ, Salgado FJ, Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother. 2009;58(11):1723-47. doi:10.1007/s00262-009-0728-1.
28. Yu DM, Slaitini L, Gysbers V, Riekhoff AG, Kahne T, Knott HM, et al. Soluble CD26 / dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro independent of dipeptidyl peptidase enzyme activity and adenosine deaminase binding. Scand J Immunol. 2011;73(2):102-11. doi:10.1111/j.1365-3083.2010.02488.x.
29. Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011;60(7):1917-25. doi:10.2337/db10-1707.
30. Bauvois B, Djavaheri-Mergny M, Rouillard D, Dumont J, Wietzerbin J. Regulation of CD26/DPPIV gene expression by interferons and retinoic acid in tumor B cells. Oncogene. 2000;19(2):265-72. doi:10.1038/sj. onc.1203292.
31. Mattern T, Reich C, Duchrow M, Ansorge S, Ulmer AJ, Flad HD. Antibody-induced modulation of CD26 surface expression. Immunology. 1995;84(4):595-600.
32. Wang Z, Grigo C, Steinbeck J, von Horsten S, Amann K, Daniel C. Soluble DPP4 originates in part from bone marrow cells and not from the kidney. Peptides. 2014;57:109-17. doi:10.1016/j. peptides.2014.05.006.
33. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153-65. doi:10.1016/j. cmet.2006.01.004.
34. Drucker DJ. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert opinion on investigational drugs. 2003;12(1):87-100. doi:10.1517/13543784.12.1.87.
35. Fleischer B. CD26: a surface protease involved in T-cell activation. Immunology today. 1994;15(4):180-4. doi:10.1016/0167-5699(94)90316-6.
36. Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes care. 2002;25(5):869-75.
37. Sell H, Bluher M, Kloting N, Schlich R, Willems M, Ruppe F, et al. Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes care. 2013;36(12):4083-90. doi:10.2337/dc13-0496.
38. Zhong J, Maiseyeu A, Davis SN, Rajagopalan S. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circulation research. 2015;116(8):1491-504. doi:10.1161/CIRCRESAHA.116.305665.
39. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. Bmj. 2012;344:e1369. doi:10.1136/bmj. e1369.
40. Wu D, Li L, Liu C. Efficacy and safety ofdipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes, obesity & metabolism. 2014;16(1):30-7. doi:10.1111/dom.12174.
41. Liu SC, Tu YK, Chien MN, Chien KL. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes, obesity & metabolism. 2012;14(9):810-20. doi:10.1111/j.1463-1326.2012.01606.x.
42. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. The Cochrane database of systematic reviews. 2008;2:CD006739. doi:10.1002/14651858. CD006739. pub2.
43. Kumar KV, Gupta AK. Clinical audit of patients using DPP4 inhibitors in longstanding type 2 diabetes. Diabetes & metabolic syndrome. 2014. doi:10.1016/j. dsx.2014.04.031.
44. Ferreira L, Teixeira-de-Lemos E, Pinto F, Parada B, Mega C, Vala H, et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm. 2010;2010:592760. doi:10.1155/2010/592760.
45. Lu HY, Huang CY, Shih CM, Chang WH, Tsai CS, Lin FY, et al. Dipeptidyl peptidase-4 inhibitor decreases abdominal aortic aneurysm formation through GLP-1-dependent monocytic activity in mice. PloS one. 2015;10(4): e0121077. doi:10.1371/journal. pone.0121077.
46. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005;54(1):146-51.
47. Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation. 2011; 124(21):2338-49. doi:10.1161/CIRCULATIONAHA.111.041418.
48. Huang CY, Shih CM, Tsao NW, Lin YW, Huang PH, Wu SC, et al. Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells. Br J Pharmacol. 2012;167(7):1506-19. doi:10.1111/j.1476-5381.2012.02102.x.
49. Cernea S, Raz I. Therapy in the early stage: incretins. Diabetes care. 2011;34 Suppl 2:S264-71. doi:10.2337/dc11-s223.
50. Bostick B, Habibi J, Ma L, Aroor A, Rehmer N, Hayden MR, et al. Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity. Metabolism: clinical and experimental. 2014;63(8):1000-11. doi:10.1016/j. metabol.2014.04.002.
51. Hirakawa H, Zempo H, Ogawa M, Watanabe R, Suzuki J, Akazawa H, et al. A DPP-4 inhibitor suppresses fibrosis and inflammation on experimental autoimmune myocarditis in mice. PloS one. 2015;10(3):e0119360. doi:10.1371/journal. pone.0119360.
52. KajiK, YoshijiH, IkenakaY, NoguchiR, AiharaY, DouharaA, etal. Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression ofactivated hepatic stellate cell in rats. J Gastroenterol. 2013. doi:10.1007A00535013-0783-4.
53. Kanasaki K, Shi S, Kanasaki M, He J, Nagai T, Nakamura Y, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes. 2014;63(6):2120-31. doi:10.2337/db13-1029.
54. Sun AL, Deng JT, Guan GJ, Chen SH, Liu YT, Cheng J, et al Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease. Diabetes & vascular disease research. 2012;9(4):301-8. doi:10.1177/1479164111434318.
55. Stefanovic V, Ardaillou N, Vlahovic P, Placier S, Ronco P, Ardaillou R. Interferon-gamma induces dipeptidylpeptidase IV expression in human glomerular epithelial cells. Immunology. 1993;80(3):465-70.
56. Yang J, Campitelli J, Hu G, Lin Y, Luo J, Xue C. Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin. Life sciences. 2007;81(4):272-9. doi:10.1016/j. lfs.2007.04.040.
57. Panchapakesan U, Mather A, Pollock C. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease. Clinical science. 2013;124(1):17-26. doi:10.1042/CS20120167.
58. Mitic B, Lazarevic G, Vlahovic P, Rajic M, Stefanovic V. Diagnostic value of the aminopeptidase N, N-acetyl-beta-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies. Renal failure. 2008;30(9):896-903. doi:10.1080/08860220802359048.
59. Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther. 2012;340(2):248-55. doi:10.1124/jpet.111.186866.
60. Mega C, de Lemos ET, Vala H, Fernandes R, Oliveira J, Mascarenhas-Melo F, et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Experimental diabetes research. 2011;2011:162092. doi:10.1155/2011/162092.
61. Glorie LL, Verhulst A, Matheeussen V, Baerts L, Magielse J, Hermans N, et al. DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury. American journal of physiology Renal physiology. 2012; 303(5):F681-8. doi:10.1152/ajprenal.00075.2012.
62. Sortino MA, Sinagra T, Canonico PL. Linagliptin: a thorough characterization beyond its clinical efficacy. Frontiers in endocrinology. 2013;4:16. doi:10.3389/fendo.2013.00016.
63. Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, von Eynatten M. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes care. 2013;36(11):3460-8. doi:10.2337/dc13-0323.
64. Graefe-Mody U, Giessmann T, Ring A, Iovino M, Woerle HJ. A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects. Clinical therapeutics. 2011; 33(8):1096-103. doi:10.1016/j. clinthera.2011.07.005.
65. Min HS, Kim JE, Lee MH, Song HK, Kang YS, Lee MJ, et al. Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction. Lab Invest. 2014;94(6):598-607. doi:10.1038/labinvest.2014.50.
66. Wang W, Koka V, Lan HY. Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology. 2005;10(1):48-56. doi:10.1111/j.1440-1797.2005.00334.x.
67. Eisenberg LM, Markwald RR. Molecular regulation of atrioventricular valvuloseptal morphogenesis. Circulation research. 1995;77(1):1-6.
68. Piera-Velazquez S, Li Z, Jimenez SA. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. The American journal of pathology. 2011;179(3):1074-80. doi:10.1016/j. ajpath.2011.06.001.
69. Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. Journal of the American Society of Nephrology: JASN. 2008;19(12):2282-7.
70. Strutz F, Zeisberg M. Renal fibroblasts and myofibroblasts in chronic kidney disease. Journal of the American Society of Nephrology: JASN. 2006;17(11): 2992-8. doi:10.1681/ASN.2006050420.
71. Charytan DM, Padera R, Helfand AM, Zeisberg M, Xu X, Liu X, et al. Increased concentration of circulating angiogenesis and nitric oxide inhibitors induces endothelial to mesenchymal transition and myocardial fibrosis in patients with chronic kidney disease. Int J Cardiol. 2014;176(1):99-109. doi:10.1016/j. ijcard.2014.06.062.
72. Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 2007;67(21):10123-8.
73. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007;13(8):952-61.
74. Potenta S, Zeisberg E, Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. Br J Cancer. 2008;99(9):1375-9.
75. Xu X, Friehs I, Zhong Hu T, Melnychenko I, Tampe B, Alnour F, et al. Endocardial fibroelastosis is caused by aberrant endothelial to mesenchymal transition. Circulation research. 2015;116(5):857-66. doi:10.1161/CIRCRESAHA.116.305629.
76. Xu X, Tan X, Tampe B, Nyamsuren G, Liu X, Maier LS, et al. Epigenetic balance of aberrant Rasal1 promoter methylation and hydroxymethylation regulates cardiac fibrosis. Cardiovasc Res. 2015;105(3):279-91. doi:10.1093/cvr/cvv015.
77. Xu X, Tan X, Tampe B, Sanchez E, Zeisberg M, Zeisberg EM. Snail is a direct target of hypoxia-inducible factor 1alpha (HIF1alpha) in hypoxia-induced endothelial to mesenchymal transition of human coronary endothelial cells. J Biol Chem. 2015;290(27):16653-64. doi:10.1074/jbc. M115.636944.
78. Zeisberg M, Zeisberg EM. Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin. Kidney international. 2015;88(3): 429-31. doi:10.1038/ki.2015.175.
79. Shi S, Srivastava SP, Kanasaki M, He J, Kitada M, Nagai T, et al. Interactions of DPP-4 and integrin beta1 influences endothelial-to-mesenchymal transition. Kidney international. 2015;88(3):479-89. doi:10.1038/ki.2015.103.
80. Pozzi A, Zent R. Extracellular matrix receptors in branched organs. Curr Opin Cell Biol. 2011;23(5):547-53. doi:10.1016/j. ceb.2011.04.003.
81. Pozzi A, Zent R. Integrins: sensors of extracellular matrix and modulators of cell function. Nephron Exp Nephrol. 2003;94(3):e77-84. doi:72025.
82. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002; 110(6):673-87.
83. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. J Biol Chem. 2000;275(29):21785-8. doi:10.1074/jbc. R000003200.
84. Park EJ, Yuki Y, Kiyono H, Shimaoka M. Structural basis of blocking integrin activation and deactivation for anti-inflammation. J Biomed Sci. 2015;22:51. doi:10.1186/s12929-015-0159-6.
85. Ratnikov BI, Partridge AW, Ginsberg MH. Integrin activation by talin. J Thromb Haemost. 2005;3(8):1783-90. doi:10.1111/j.1538-7836.2005.01362.x.
86. Luo BH, Carman CV, Springer TA. Structural basis ofintegrin regulation and signaling. Annu Rev Immunol. 2007;25:619-47. doi:10.1146/annurev. immunol.25.022106.141618.
87. Arnaout MA, Goodman SL, Xiong JP. Structure and mechanics of integrin-based cell adhesion. Curr Opin Cell Biol. 2007;19(5):495-507. doi:10.1016/j. ceb.2007.08.002.
88. Zent R, Yan X, Su Y, Hudson BG, Borza DB, Moeckel GW, et al. Glomerular injury is exacerbated in diabetic integrin alpha1-null mice. Kidney international. 2006;70(3):460-70. doi:10.1038/sj. ki.5000359.
89. Chen X, Abair TD, Ibanez MR, Su Y, Frey MR, Dise RS, et al. Integrin alpha1beta1 controls reactive oxygen species synthesis by negatively regulating epidermal growth factor receptor-mediated Rac activation. Mol Cell Biol. 2007;27(9):3313-26. doi:10.1128/MCB.01476-06.
90. Yeh YC, Wei WC, Wang YK, Lin SC, Sung JM, Tang MJ. Transforming growth factor--beta}1 induces Smad3-dependent-beta}1 integrin gene expression in epithelial-to-mesenchymal transition during chronic tubulointerstitial fibrosis. The American journal of pathology. 2010;177(4):1743-54. doi:10.2353/ajpath.2010.091183.
91. Hamzeh MT, Sridhara R, Alexander LD. Cyclic stretch-induced TGF-beta1 and fibronectin expression is mediated by beta1-integrin through c-Src-and STAT3-dependent pathways in renal epithelial cells. American journal of physiology Renal physiology. 2015;308(5):F425-36. doi:10.1152/ajprenal.00589.2014.
92. Tang XH, Huang SM, Tan SQ, Ma YL. Effect of rosiglitazone on integrin beta1 expression and apoptosis of proximal tubular cell exposed to high glucose. Sichuan Da Xue Xue Bao Yi Xue Ban. 2007;38(2):291-4.
93. Glynne PA, Picot J, Evans TJ. Coexpressed nitric oxide synthase and apical beta(1) integrins influence tubule cell adhesion after cytokine-induced injury. Journal of the American Society of Nephrology: JASN. 2001;12(11):2370-83.
94. Elias BC, Mathew S, Srichai MB, Palamuttam R, Bulus N, Mernaugh G, et al. The integrin beta1 subunit regulates paracellular permeability of kidney proximal tubule cells. J Biol Chem. 2014;289(12):8532-44. doi:10.1074/jbc. M113.526509.
95. Lal H, Verma SK, Foster DM, Golden HB, Reneau JC, Watson LE, et al. Integrins and proximal signaling mechanisms in cardiovascular disease. Front Biosci (Landmark Ed). 2009;14:2307-34.
96. Srichai M, Zent R. Integrin structure and function. In: Zent R, Pozzi A, editors. Cell-Extracellular Matrix Interactions in Cancer. New York: Springer; 2010. p. 19-41.
97. Yuan X, Wang W, Wang J, Yin X, Zhai X, Wang L, et al. Down-regulation of integrin beta1 and focal adhesion kinase in renal glomeruli under various hemodynamic conditions. PloS one. 2014;9(4):e94212. doi:10.1371/journal. pone.0094212.
98. Liu S, Kapoor M, Denton CP, Abraham DJ, Leask A. Loss of beta1 integrin in mouse fibroblasts results in resistance to skin scleroderma in a mouse model. Arthritis and rheumatism. 2009;60(9):2817-21. doi:10.1002/art.24801.
99. Sato T, Yamochi T, Yamochi T, Aytac U, Ohnuma K, McKee KS, et al. CD26 regulates p38 mitogen-activated protein kinase-dependent phosphorylation ofintegrin beta1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299. Cancer Res. 2005;65(15):6950-6. doi:10.1158/0008-5472. CAN-05-0647.
100. Medici D, Shore EM, Lounev VY, Kaplan FS, Kalluri R, Olsen BR. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med. 2010; 16(12):1400-6. doi:10.1038/nm.2252.
101. Nagai T, Kanasaki M, Srivastava S, Nakamura Y, Ishigaki Y, Kitada M et al. N-acetyl-seryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-Mesenchymal transition. BioMed research international. 2014;2014. doi:10.1155/2014/696475.
102. Srivastava SP, Koya D, Kanasaki K. MicroRNAs in kidney fibrosis and diabetic nephropathy: roles on EMT and EndMT. BioMed research international. 2013;2013:125469. doi:10.1155/2013/125469.
103. Chen PY, Qin L, Barnes C, Charisse K, Yi T, Zhang X, et al. FGF regulates TGF-beta signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression. Cell reports. 2012;2(6):1684-96. doi:10.1016/j. celrep.2012.10.021.
104. Cheng MF, Chen LJ, Wang MC, Hsu CT, Cheng JT. Decrease of FGF receptor (FGFR) and interstitial fibrosis in the kidney ofstreptozotocin-induced diabetic rats. Hormone and metabolic research = Hormon-und Stoffwechselforschung = Hormones et metabolisme. 2014;46(1):1-7. doi:10.1055/s-0033-1349090.
105. Zhong X, Chung AC, Chen HY, Meng XM, Lan HY. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. Journal of the American Society of Nephrology: JASN. 2011;22(9):1668-81. doi:10.1681/ASN.2010111168
106. Lagendijk AK, Goumans MJ, Burkhard SB, Bakkers J. MicroRNA-23 restricts cardiac valve formation by inhibiting Has2 and extracellular hyaluronic acid production. Circulation research. 2011;109(6):649-57. doi:10.1161/CIRCRESAHA.111.247635.
107. Rinkevich Y, Walmsley GG, Hu MS, Maan ZN, Newman AM, Drukker M, et al. Skin fibrosis. Identification and isolation of a dermal lineage with intrinsic fibrogenic potential. Science. 2015;348(6232):aaa2151. doi:10.1126/science. aaa2151.
108. Takai S, Sakonjo H, Jin D. Significance ofvascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats. J Pharmacol Sci.2014;125(4):386-93.
109. Yamada K, Hayashi M, Du W, Ohnuma K, Sakamoto M, Morimoto C, et al. Localization of CD26/DPPIV in nucleus and its nuclear translocation enhanced by anti-CD26 monoclonal antibody with anti-tumor effect. Cancer Cell Int. 2009;9:17. doi:10.1186/1475-2867-9-17.
110. Shi S, Kanasaki K, Koya D. Linagliptin but not Sitagliptin inhibited transforming growth factor-β2-induced endothelial DPP-4 activity and the endothelial-mesenchymal transition. Biochem Biophys Res Commun. 2016 Jan 27. pii: S0006-291X(16)30154-1. doi:10.1016/j. bbrc.2016.01.154.